Related Experiment Video
Updated: Mar 9, 2026
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Identification and functional characterization of a novel MTFMT mutation associated with selective vulnerability of
Roberta La Piana1,2, Woranontee Weraarpachai3,4, Luis H Ospina5
1Laboratory of Neurogenetics of Motion, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.
Abstract:
Mitochondrial protein synthesis is initiated by formylated tRNA-methionine, which requires the activity of MTFMT, a methionyl-tRNA formyltransferase. Mutations in MTFMT have been associated with Leigh syndrome, early-onset mitochondrial leukoencephalopathy, microcephaly, ataxia, and cardiomyopathy. We identified compound heterozygous MTFMT mutations in a patient with a mild neurological phenotype and late-onset progressive visual impairment. MRI studies documented a progressive and selective involvement of the retrochiasmatic visual pathway. MTFMT was undetectable by immunoblot analysis of patient fibroblasts, resulting in specific defects in mitochondrial protein synthesis and assembly of the oxidative phosphorylation complexes. This report expands the clinical and MRI phenotypes associated with MTFMT mutations, illustrating the complexity of genotype-phenotype relationships in mitochondrial translation disorders.
Insights
Mutations in the mitochondrial methionyl-tRNA formyltransferase (MTFMT) gene can cause visual impairment. This study details a patient with late-onset visual loss due to MTFMT mutations, expanding known disease phenotypes.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Mitochondrial protein synthesis is crucial for cellular energy production.
- Formylated tRNA-methionine initiates mitochondrial translation, dependent on methionyl-tRNA formyltransferase (MTFMT).
- MTFMT mutations are linked to severe neurological and cardiac conditions.
Observation:
- A patient presented with mild neurological symptoms and progressive visual impairment.
- Magnetic resonance imaging (MRI) revealed selective involvement of the retrochiasmatic visual pathway.
- MTFMT protein was undetectable in patient fibroblasts.
Findings:
- Compound heterozygous MTFMT mutations were identified in the patient.
- Defects in mitochondrial protein synthesis and oxidative phosphorylation were observed.
- The patient's phenotype expanded the known clinical spectrum of MTFMT-related disorders.
Implications:
- This case broadens the understanding of MTFMT mutation phenotypes, including late-onset visual impairment.
- It highlights the diagnostic challenges and genotype-phenotype variability in mitochondrial translation disorders.
- Further research into MTFMT function may reveal new therapeutic targets for mitochondrial diseases.
More Related Videos
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
10:33Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:17Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase